Lipocine (LPCN): Director bought ~$112K
John W. Higuchi, Director at Lipocine, bought ~$112K of Lipocine shares.
- ~$112K
- Approx. value · 75K sh @ $1.49
- 391K
- Holds after · shares reported
- Traded
- Nov 20, 2026
- Filed
- Nov 20, 2026
What stands out in this filing
- The purchase added 23.7% to the shares this insider held before it; the filing reports 391,365 shares afterwards.
- 75,000 shares at an average of $1.49 each, as reported on the form.
- The first open-market purchase by this insider in 0 months.
- 1 other insider at LPCN also bought in the open market within 30 days.
- LPCN closed at $1.48 on Nov 20, 2026, within 3% of its 52-week low, after a 14% drop over the previous 30 trading days.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 28, 2026InsiderDirector purchased ~$27K of LPCN shares in the open market
- Sep 29, 2026InsiderDirector purchased ~$19K of LPCN shares in the open market
- Sep 30, 2026InsiderDirector purchased ~$36K of LPCN shares in the open market
- Nov 5, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 12, 2026InsiderCEO purchased ~$39K of LPCN shares in the open market
- Nov 13, 2026InsiderCEO purchased ~$40K of LPCN shares in the open market
- Nov 19, 2026InsiderDirector purchased ~$113K of LPCN shares in the open market
- Nov 20, 2026 · this disclosureInsiderDirector purchased ~$112K of LPCN shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Lipocine
For Lipocine, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LPCN page.
Other recent filings by John W. Higuchi, Director
- SEC Form 4 at Lipocine (LPCN)Oct 2, 2026
- SEC Form 4 at Lipocine (LPCN)Oct 2, 2026
- SEC Form 4 at Lipocine (LPCN)Oct 1, 2026
- SEC Form 4 at Lipocine (LPCN)Apr 7, 2026
- SEC Form 4 at Lipocine (LPCN)Apr 6, 2026
The full history of John W. Higuchi, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Lipocine (LPCN) insider traded, and how much?
John W. Higuchi, Director at Lipocine, bought ~$112K of Lipocine shares. 75K shares at $1.49, open market.
When did it happen, and when was it made public?
Traded: Nov 20, 2026. Filed: Nov 20, 2026.
What stands out in this filing?
The purchase added 23.7% to the shares this insider held before it; the filing reports 391,365 shares afterwards. 75,000 shares at an average of $1.49 each, as reported on the form. The first open-market purchase by this insider in 0 months.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Lipocine recently?
For Lipocine, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the LPCN page.
Does this mean LPCN stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Lipocine
- SEC Form 4Nov 20, 2026
- SEC Form 4Nov 13, 2026
- SEC Form 4Nov 13, 2026
- SEC Form 4Oct 2, 2026
- SEC Form 4Oct 2, 2026
- SEC Form 4Oct 1, 2026
Everything OQRO holds on this company is on its LPCN page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
